Spatiotemporal Controllable Sono-Nanovaccines Driven by Free-Field Based Whole-Body Ultrasound for Personalized Cancer Therapy
© 2024 The Authors. Advanced Science published by Wiley‐VCH GmbH..
Therapeutic cancer vaccines fail to produce satisfactory outcomes against solid tumors since vaccine-induced anti-tumor immunity is significantly hampered by immunosuppression. Generating an in situ cancer vaccine targeting immunological cold tumor microenvironment (TME) appears attractive. Here, a type of free-field based whole-body ultrasound (US)-driven nanovaccines are constructed, named G5-CHC-R, by conjugating the sonosensitizer, Chenghai chlorin (CHC) and the immunomodulator, resiquimod (R848) on top of a super small-sized dendrimeric nanoscaffold. Once entering tumors, R848 can be cleaved from a hypoxia-sensitive linker, thus modifying the TME via converting macrophage phenotypes. The animals bearing orthotopic pancreatic cancer with intestinal metastasis and breast cancer with lung metastasis are treated with G5-CHC-R under a free-field based whole-body US system. Benefit from the deep penetration capacity and highly spatiotemporal selectiveness, G5-CHC-R triggered by US represented a superior alternative for noninvasive irradiation of deep-seated tumors and magnification of local immune responses via driving mass release of tumor antigens and "cold-warm-hot" three-state transformation of TME. In addition to irradiating primary tumors, a robust adaptive anti-tumor immunity is potentiated, leading to successful induction of systemic tumor suppression. The sono-nanovaccines with good biocompatibility posed wide applicability to a broad spectrum of tumors, revealing immeasurable potential for translational research in oncology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) - 11(2024), 14 vom: 24. Apr., Seite e2307920 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Immunologic |
|---|
| Anmerkungen: |
Date Completed 11.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/advs.202307920 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367975734 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367975734 | ||
| 003 | DE-627 | ||
| 005 | 20240425232815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/advs.202307920 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM367975734 | ||
| 035 | |a (NLM)38308196 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spatiotemporal Controllable Sono-Nanovaccines Driven by Free-Field Based Whole-Body Ultrasound for Personalized Cancer Therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Advanced Science published by Wiley‐VCH GmbH. | ||
| 520 | |a Therapeutic cancer vaccines fail to produce satisfactory outcomes against solid tumors since vaccine-induced anti-tumor immunity is significantly hampered by immunosuppression. Generating an in situ cancer vaccine targeting immunological cold tumor microenvironment (TME) appears attractive. Here, a type of free-field based whole-body ultrasound (US)-driven nanovaccines are constructed, named G5-CHC-R, by conjugating the sonosensitizer, Chenghai chlorin (CHC) and the immunomodulator, resiquimod (R848) on top of a super small-sized dendrimeric nanoscaffold. Once entering tumors, R848 can be cleaved from a hypoxia-sensitive linker, thus modifying the TME via converting macrophage phenotypes. The animals bearing orthotopic pancreatic cancer with intestinal metastasis and breast cancer with lung metastasis are treated with G5-CHC-R under a free-field based whole-body US system. Benefit from the deep penetration capacity and highly spatiotemporal selectiveness, G5-CHC-R triggered by US represented a superior alternative for noninvasive irradiation of deep-seated tumors and magnification of local immune responses via driving mass release of tumor antigens and "cold-warm-hot" three-state transformation of TME. In addition to irradiating primary tumors, a robust adaptive anti-tumor immunity is potentiated, leading to successful induction of systemic tumor suppression. The sono-nanovaccines with good biocompatibility posed wide applicability to a broad spectrum of tumors, revealing immeasurable potential for translational research in oncology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a nanovaccines | |
| 650 | 4 | |a tumor associated macrophages | |
| 650 | 4 | |a tumor microenvironment modulation | |
| 650 | 4 | |a ultrasound‐driven | |
| 650 | 4 | |a whole‐body sonodynamic therapy | |
| 650 | 7 | |a Nanovaccines |2 NLM | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 700 | 1 | |a Li, Guangzhe |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Jianlong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yiming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaomai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Guanyi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhihao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jinrong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zejia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ruimin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chengdong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Liu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Fangfang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Weijie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xuejian |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Xiaojun |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Kun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced science (Weinheim, Baden-Wurttemberg, Germany) |d 2014 |g 11(2024), 14 vom: 24. Apr., Seite e2307920 |w (DE-627)NLM252851455 |x 2198-3844 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:14 |g day:24 |g month:04 |g pages:e2307920 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/advs.202307920 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 14 |b 24 |c 04 |h e2307920 | ||